The Strange case of Meningitis B and the mRNA industry.

When the meningitis B vaccine was created over 10 years ago, the UK decided that it couldn’t make it a“recommended” vaccine on the normal vaccine schedule as it cost rather a lot - over £200 as I recall - and the dangers were rather minimal with only a few cases per year.